Technology Bundle ID
TAB-2734

Select M. tuberculosis Peptides as Mucosal Vaccines Against Pulmonary Tuberculosis

Linked ID
E-192-2013-0
Lead Inventors
Suraj Sable (CDC)
Co-Inventors
Bonnie Plikaytis (CDC)
Mani Cheruvu (CDC)
Rama Amara (Emory University)
Thomas Shinnick (CDC)
Development Stages
Pre-clinical (in vivo)
Development Status
  • In vitro data available
  • In vivo data available (animal)
ICs
CDC
This CDC-developed technology relates to novel vaccines or boosters directed against pulmonary tuberculosis. There is currently only a single vaccine against tuberculosis, the (Bacillus Calmette-Guérin) BCG vaccine. Reports suggest widely variable effectiveness for the BCG vaccine and that BCG administration has very limited success against prevention of the primary pulmonary form of the disease. With a marginally useful vaccine and rising rates of multidrug-resistant and extensively drug-resistant (MDR and XDR) tuberculosis strains, it is clear there is a public health need that must be met.

Researchers working at CDC have developed improved vaccine formulations and processes of delivery for enhancing the immune response against M. tuberculosis. These improvements may be implemented as stand-alone vaccines or in conjunction with BCG as part of a prime-boost strategy. Intranasal immunization engenders a strong immune response in the lungs, which is beneficial because the M. tuberculosis pathogen primarily gains entry through the respiratory/alveolar mucosa. By specifically stimulating mucosal immunity with select recombinant M. tuberculosis polypeptides at the typical site of pathogen entry, it is envisioned that these formulations and delivery methods will be able to prevent M. tuberculosis infection and subsequent pulmonary tuberculosis disease.
Commercial Applications
  • Tuberculosis vaccine development and improvement
  • Public health and BCG vaccination programs
Competitive Advantages
  • Versatile, has potential as stand-alone vaccine or booster for use with current BCG vaccine
  • Peptides specifically selected for generating mucosal immunity, to address the protective-failings of the BCG vaccine
  • Potential for needle-free delivery that elicits robust, well-directed immune response

Request More Info

Licensing Contact: